CurrentPremera Blue Cross of WashingtonPolicy N/A

Optilume Urethral Drug-Coated Balloon for Recurrent Urethral Stricture

Customize your policy alerts

Sign up for all premerabluecrossofwashington policy alerts

Know when premerabluecrossofwashington releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy addresses medical necessity and investigational status for the Optilume urethral drug-coated balloon in adult men with recurrent anterior urethral stricture and the Optilume BPH Catheter System for lower urinary tract symptoms secondary to benign prostatic hyperplasia. It also specifies documentation and billing codes for provider review.

Policy Summary

PayerPremera Blue Cross of Washington

PolicyOptilume Urethral Drug-Coated Balloon for Recurrent Urethral Stricture

Policy CodePolicy N/A

Change TypeNew policy

Effective DateFeb 5, 2027

Next Review DateN/A

Key ActionSubmit office visit notes documenting recurrent bulbar urethral stricture, length of 3 cm or less, and failed prior treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤3 cmMaximum covered stricture length

InvestigationalBPH catheter system coverage status

83.2% vs 21.7%One-year freedom from repeat intervention

20–80 ccIPDCB prostate volume range

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentPremera Blue Cross of WashingtonPolicy N/A

Optilume Urethral Drug-Coated Balloon for Recurrent Urethral Stricture

Customize your policy alerts

Sign up for all premerabluecrossofwashington policy alerts

Know when premerabluecrossofwashington releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPremera Blue Cross of Washington

PolicyOptilume Urethral Drug-Coated Balloon for Recurrent Urethral Stricture

Policy CodePolicy N/A

Change TypeNew policy

Effective DateFeb 5, 2027

Next Review DateN/A

Key ActionSubmit office visit notes documenting recurrent bulbar urethral stricture, length of 3 cm or less, and failed prior treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤3 cmMaximum covered stricture length

InvestigationalBPH catheter system coverage status

83.2% vs 21.7%One-year freedom from repeat intervention

20–80 ccIPDCB prostate volume range

2Contraindications for both devices

Medical Necessity and Investigational Uses

Medically Necessary Recurrent Bulbar Urethral Stricture Treatment

The Optilume urethral drug-coated balloon may be considered medically necessary when all of the following are met.

Covered medical necessity criteria

Anatomic location: The stricture is located in the bulbar urethra
Stricture length: The stricture is 3 cm or less in length≤3 cm
Prior treatment failure: The stricture is recurrent, having failed prior endoscopic treatment

Investigational Urethral Stricture Uses

The Optilume urethral drug-coated balloon is considered investigational in other circumstances.

Investigational urethral stricture circumstances

Penile urethral stricture: Treatment of penile urethral stricture
Primary treatment: First-time (primary) treatment
Repeated device use: Repeated use of the device

Optilume BPH Catheter System

The Optilume BPH Catheter System is considered investigational.

Investigational BPH use: Treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia using the Optilume BPH Catheter System

Urethral Drug-Coated Balloon

The Optilume urethral drug-coated balloon may be considered medically necessary when criteria are met.

Medically necessary urethral stricture use: Recurrent anterior (bulbar) urethral stricture in an adult man, with all additional policy criteria met.

Specific additional criteria are not stated in this document window.

Other Anterior Urethral Stricture Use

The Optilume urethral drug-coated balloon is considered investigational in other circumstances.

Investigational urethral stricture use: Treatment of anterior urethral stricture outside recurrent bulbar urethral stricture in adult men meeting policy criteria.

The policy history does not provide additional subcriteria in this document window.

BPH Use

The Optilume BPH Catheter System is considered investigational.

BPH catheter system: Treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

The policy history characterizes this use as investigational.

The Optilume urethral drug-coated balloon is considered investigational for anterior urethral stricture when used outside the covered indication for recurrent bulbar disease in adult men. This includes penile urethral stricture, first-time (primary) treatment, and repeated use of the device. The Optilume BPH Catheter System is also considered investigational for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Do not use either device in patients with known hypersensitivity to paclitaxel or structurally related compounds or in the presence of an active urinary tract infection. Because paclitaxel may remain detectable in semen after treatment, barrier contraception is advised for men whose partners may become pregnant.

Billing Codes and Clinical Thresholds

CPT CodesCPT

52284	Drug delivery using a drug-coated balloon for male treatment of urethral stricture using an endoscope.
52443	Cystourethroscopy with initial transurethral anterior prostate commissurotomy with a nondrug-coated balloon catheter followed by therapeutic drug delivery into the prostate by a drug-coated balloon catheter, including transrectal ultrasound and fluoroscopy, when performed.

HCPCS CodesHCPCS

C1889

Implantable/insertable device, not otherwise classified

Recurrent bulbar urethral stricture

Qualifying stricture locationBulbar urethra

Maximum qualifying length3 cm or less

Prior treatment requirementRecurrent stricture after failed prior endoscopic treatment

Prostate volume for IPDCB consideration

Prostate volume20-80 cc

Clinical useConsideration of intraprostatic drug-coated balloon for LUTS/BPH

Additional guideline condition

Documentation and Coverage Decision Guidance

Documentation Required

Required Clinical Documentation

Submit the patient's medical records for review to demonstrate that the medical-necessity criteria are met. Records must include office visit notes with the relevant history and physical documenting that the Optilume urethral drug-coated balloon is being used to treat recurrent bulbar urethral stricture.

Document that the patient is an adult man with recurrent bulbar urethral stricture.
Document that the stricture is 3 cm or less in length.
Document the prior treatment that failed to treat the condition, including prior endoscopic treatment.

Denial Risk

Noncovered Urethral Stricture Circumstances

The Optilume urethral drug-coated balloon is investigational for anterior urethral stricture in circumstances outside the covered indication and may be denied.

Clinical Background

The related Optilume BPH Catheter System is used in the context of benign prostatic hyperplasia, a nonmalignant enlargement of the prostate that can cause bladder outlet obstruction and lower urinary tract symptoms. The policy considers this BPH-related use investigational.

Policy Terminology

Urethral stricture

DefinitionA fibrotic narrowing of the urethral lumen caused by scarring of the surrounding corpus spongiosum

Anterior urethral segmentsMeatus, fossa navicularis, penile urethra, and bulbar urethra

Clinical effectCan obstruct urine flow and produce obstructive lower urinary tract symptoms

Optilume drug-coated balloon

Device definitionA dual-lumen, over-the-wire balloon catheter with a semi-compliant balloon coated with paclitaxel along its working length

Mechanical actionDilates the strictured segment by expanding the balloon and exerting radial force

Policy Summary

PayerPremera Blue Cross of Washington

PolicyOptilume Urethral Drug-Coated Balloon for Recurrent Urethral Stricture

Policy CodePolicy N/A

Change TypeNew policy

Effective DateFeb 5, 2027

Next Review DateN/A

Key ActionSubmit office visit notes documenting recurrent bulbar urethral stricture, length of 3 cm or less, and failed prior treatment.

SourceLink

On This Page

Without an obstructing median lobe

Prostatic urethral length for IPDCB consideration

Prostatic urethral length32-55 mm

Clinical useConsideration of intraprostatic drug-coated balloon for LUTS/BPH

Guideline contextConditional recommendation; evidence level Grade C

Penile urethral stricture
First-time (primary) treatment
Repeated use of the device

Denial Risk

BPH Indication Is Investigational

The Optilume BPH Catheter System is considered investigational for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).

BPH-related lower urinary tract symptoms are not a covered indication under this policy.

Denial Risk

Unmet Covered-Indication Criteria

Coverage may be denied when the covered-indication criteria are not met. The Optilume urethral drug-coated balloon may be considered medically necessary only for recurrent bulbar urethral stricture in adult men when all required criteria are satisfied.

The stricture must be 3 cm or less in length.
The stricture must be recurrent and have failed prior endoscopic treatment.

Denial Risk

Nonqualifying Urethral Stricture Use

Use of the Optilume urethral drug-coated balloon for anterior urethral stricture outside the medically necessary criteria is considered investigational.

The covered indication requires recurrent bulbar urethral stricture in an adult man.
Other circumstances, including penile location, primary treatment, or repeated device use, are investigational.

Denial Risk

BPH Catheter System Is Investigational

Do not represent the Optilume BPH Catheter System as a covered treatment for lower urinary tract symptoms secondary to BPH. The policy considers this use investigational.

Review the indication before submitting the device for coverage.
BPH-related lower urinary tract symptoms are considered investigational under this policy.

Drug delivery concept

Transfers paclitaxel locally to the urethral wall to inhibit fibroblast proliferation and scar re-formation

Benign prostatic hyperplasia (BPH)

DefinitionNonmalignant enlargement of the prostate

Anatomic effectCan cause bladder outlet obstruction

Clinical effectsCan cause lower urinary tract symptoms, including voiding and storage symptoms

Lower urinary tract symptoms (LUTS)

DefinitionSymptoms associated with bladder outlet or urinary tract dysfunction

Voiding symptomsWeak stream, hesitancy, straining, intermittency, and incomplete emptying

Storage symptomsUrinary frequency, urgency, and nocturia

BPH

AbbreviationBPH

Expanded termBenign prostatic hyperplasia

Related symptomsLower urinary tract symptoms may result from prostatic enlargement and bladder outlet obstruction

DVIU

AbbreviationDVIU

Expanded termDirect visual internal urethrotomy

Treatment contextA minimally invasive endoscopic treatment for urethral stricture disease

NCT

AbbreviationNCT

Expanded termNational clinical trial identifier

Use in policy materialsIdentifies clinical trials, including ongoing and unpublished studies

IPDCB

AbbreviationIPDCB

Expanded termIntraprostatic drug-coated balloon

Procedure descriptionA two-stage transurethral procedure using a temporary dilating balloon followed by a paclitaxel-coated balloon